Weight-loss company Noom pivots to smaller doses of compounded Wegovy
By Amina Niasse NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo ...
Read moreDetailsTag: Novo Nordisk
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
COPENHAGEN (Reuters) -Novo Nordisk (NVO) has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small ...
Read moreDetailsEli Lilly’s Zepbound outperforms Novo Nordisk’s Wegovy for weight loss in trial
(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such ...
Read moreDetailsLilly pill leads to 7.9% weight loss in late-stage trial, shares jump
(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest ...
Read moreDetailsFake Ozempic Found in US Drug Supply Chain
Amid the soaring demand for GLP-1 drugs used to treat diabetes and support weight loss, the U.S. Food and Drug ...
Read moreDetailsInvestors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
By Maggie Fick and Robin Respaut LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information ...
Read moreDetailsChina-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
(Reuters) - Eli Lilly (LLY) and Hong Kong-listed Laekna (2105.HK) will collaborate to develop an experimental obesity drug that aims ...
Read moreDetails
